Who is sponsoring NCT00560417?

NCT00560417 is sponsored by Eli Lilly and Company.

What condition does NCT00560417 study?

NCT00560417 studies Diabetes Mellitus, Type 2.

What drugs are being tested in NCT00560417?

Interventions: Insulin Lispro Protamine Suspension, Insulin Glargine.

What is the status of NCT00560417?

NCT00560417 is currently COMPLETED.

Last reviewed 2011-01-12 · How we verify

A Randomized Trial Comparing Insulin Lispro Protamine Suspension With Insulin Glargine in Subjects With Type 2 Diabetes on Oral Antihyperglycemic Medications and Exenatide

NCT00560417 Phase 3 COMPLETED Results posted

This study will compare insulin lispro protamine suspension (ILPS) and insulin glargine in combination with the patient's oral diabetes medications and exenatide, for their ability to control blood sugar in patients with type 2 diabetes.

Details

Lead sponsor	Eli Lilly and Company
Phase	Phase 3
Status	COMPLETED
Enrolment	339
Start date	2007-11
Completion	2009-12

Conditions

Diabetes Mellitus, Type 2

Interventions

Insulin Lispro Protamine Suspension
Insulin Glargine

Primary outcomes

Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF]) — Baseline, Endpoint (LOCF) up to 24 weeks
Least squares mean values were controlled for Baseline + Baseline HbA1c Group + Baseline sulfonylurea (SU) Group.

Countries

United States, Puerto Rico